Cabaletta Bio (US:CABA) — Company Overview, News & Financial Data
Cabaletta Bio develops T-cell therapies aimed at providing functional cures for autoimmune diseases.
Cabaletta Bio
Cabaletta Bio (NASDAQ:CABA) focuses on developing therapies aimed at providing a functional cure for patients with autoimmune diseases. Its approach centers on utilizing engineered T cell therapies targeting B cell-mediated autoimmune diseases, leveraging its proprietary technology to specifically target and eliminate the cells responsible for disease activity. The company's pipeline includes several projects at various stages of development, targeting a range of autoimmune disorders with the objective of achieving long-term disease remission or functional cure. Cabaletta Bio aims to transform the treatment landscape for autoimmune disease patients, offering new hope through innovative, targeted therapies.
Snapshot
Operations
Products and/or services of Cabaletta Bio
- DesCAARTes™ platform harnesses Chimeric AutoAntibody Receptor T cells designed to target and eliminate B cells causing autoimmune diseases.
- Dsg3-CAART is a therapy aimed at treating mucosal pemphigus vulgaris by selectively targeting and depleting disease-causing B cells.
- FVIII-CAART seeks to provide a potential treatment for hemophilia A by using engineered T cells to eliminate inhibitors of factor VIII.
- MuSK-CAART therapy is being developed for patients with MuSK myasthenia gravis, targeting specific B cells to alleviate symptoms.
- The collaboration with the University of Pennsylvania explores novel CAART therapies for autoimmune diseases by leveraging genetic engineering expertise and clinical insights.
- CART-TT focuses on T cell-mediated therapies to potentially treat T cell-related autoimmune and inflammatory diseases, offering a unique approach by targeting specific T cell subsets.
Cabaletta Bio executive team
- Dr. Steven A. Nichtberger M.D.Co-Founder, Chairman, CEO & President
- Dr. David J. Chang FACR, M.D., M.P.H.Chief Medical Officer
- Dr. Gwendolyn K. Binder Ph.D.President of Science & Technology
- Dr. Michael C. Milone M.D., Ph.D.Co-Founder & Co-Chair of Scientific Advisory Board
- Dr. Aimee Payne M.D., Ph.D.Co-Founder & Co-Chair of Scientific Advisory Board
- Mr. Anup Marda M.B.A.Chief Financial Officer
- Dr. Qing Sarah Yuan Ph.D.Chief Technology Officer
- Dr. Samik Basu M.D.Chief Scientific Officer
- Mr. Michael Gerard J.D.General Counsel & Secretary
- Ms. Heather Harte-Hall M.Sc.Chief Compliance Officer